Evidence map›Paper›PMID 34182936›Full record

ArticleBMC infectious diseases2021

Detection of diarrhoea associated rotavirus and co-infection with diarrhoeagenic pathogens in the Littoral region of Cameroon using ELISA, RT-PCR and Luminex xTAG GPP assays.

Rahinatou N Ghapoutsa, Maurice Boda, Rashi Gautam, Valantine Ngum Ndze, Akongnwi E Mugyia, Francois-Xavier Etoa, Michael D Bowen, Mathew D Esona

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Whole Genome Sequencing and CRISPR/Cas9 Gene Editing of EnterotoxigenicInternational journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rahinatou N GhapoutsaDepartment of Biochemistry, Faculty of Science, The University of Yaoundé 1, Yaoundé, Cameroon.
Maurice BodaDepartment of Microbiology, Faculty of Science, The University of Yaoundé 1, Yaoundé, Cameroon. bodamaurice@gmail.com.
Rashi GautamDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Valantine Ngum NdzeFaculty of Health Sciences, University of Buea, Buea, Cameroon.
Akongnwi E MugyiaDepartment of Microbiology and Parasitology, Faculty of Science, University of Buea, Buea, Cameroon.
Francois-Xavier EtoaDepartment of Microbiology, Faculty of Science, The University of Yaoundé 1, Yaoundé, Cameroon.
Michael D BowenDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
Mathew D EsonaDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Diseases Control and Prevention, Atlanta, Georgia, USA.
National Center for Immunization and Respiratory Diseases · USUniversité de Yaoundé I · CMUniversity of Buea · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the global roll-out of rotavirus vaccines (RotaTeq/Rotarix / ROTAVAC/Rotasiil), mortality and morbidity due to group A rotavirus (RVA) remains high in sub-Saharan Africa, causing 104,000 deaths and 600,000 hospitalizations yearly. In Cameroon, Rotarix™ was introduced in March 2014, but, routine laboratory diagnosis of rotavirus infection is not yet a common practice, and vaccine effectiveness studies to determine the impact of vaccine introduction have not been done. Thus, studies examining RVA prevalence post vaccine introduction are needed. The study aim was to determine RVA prevalence in severe diarrhoea cases in Littoral region, Cameroon and investigate the role of other diarrheagenic pathogens in RVA-positive cases.

methodsWe carried out a study among hospitalized children < 5 years of age, presenting with acute gastroenteritis in selected hospitals of the Littoral region of Cameroon, from May 2015 to April 2016. Diarrheic stool samples and socio-demographic data including immunization and breastfeeding status were collected from these participating children. Samples were screened by ELISA (ProSpecT™ Rotavirus) for detection of RVA antigen and by gel-based RT-PCR for detection of the VP6 gene. Co-infection was assessed by multiplexed molecular detection of diarrheal pathogens using the Luminex xTAG GPP assay.

resultsThe ELISA assay detected RVA antigen in 54.6% (71/130) of specimens, with 45, positive by VP6 RT-PCR and 54, positive using Luminex xTAG GPP. Luminex GPP was able to detect all 45 VP6 RT-PCR positive samples. Co-infections were found in 63.0% (34/54) of Luminex positive RVA infections, with Shigella (35.3%; 12/34) and ETEC (29.4%; 10/34) detected frequently. Of the 71 ELISA positive RVA cases, 57.8% (41/71) were fully vaccinated, receiving two doses of Rotarix.

conclusionThis study provides insight on RVA prevalence in Cameroon, which could be useful for post-vaccine epidemiological studies, highlights higher than expected RVA prevalence in vaccinated children hospitalized for diarrhoea and provides the trend of RVA co-infection with other enteric pathogens. RVA genotyping is needed to determine circulating rotavirus genotypes in Cameroon, including those causing disease in vaccinated children.

Indexed as

Antigens, ViralBiological AssayCameroonCapsid ProteinsChild, HospitalizedChild, PreschoolCoinfectionDiarrheaEnzyme-Linked Immunosorbent AssayFemaleHumansInfantMalePrevalenceReverse Transcriptase Polymerase Chain ReactionRotavirusAntigens, ViralCapsid ProteinsRIX4414 vaccineRotaTeqRotavirus VaccinesVaccines, AttenuatedVP6 protein, RotavirusCameroonChildhood diarrhoeaCo-infectionRotarixRotavirusRT-PCRxTAG GPP

Identifiers

PMID34182936
PMCPMC8237514
OpenAlexW3173924301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.